ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

GSK Gsk Plc

1,708.60
3.40 (0.20%)
Last Updated: 11:50:10
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  3.40 0.20% 1,708.60 1,708.60 1,709.20 1,709.60 1,699.40 1,701.60 905,179 11:50:10
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 14.27 70.3B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,705.20p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,719.80p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £70.30 billion. Gsk has a price to earnings ratio (PE ratio) of 14.27.

Gsk Share Discussion Threads

Showing 16276 to 16297 of 33075 messages
Chat Pages: Latest  663  662  661  660  659  658  657  656  655  654  653  652  Older
DateSubjectAuthorDiscuss
15/1/2018
16:12
50 day moving average has just been broken and Cutler trend has been positive since October. The share price has also broken out of the top of its Bollinger range recently for the first time in ages. Momentum and sentiment improving here so I am in agreement with Monty - although it may take a little time to reach 1425.
ygor705
15/1/2018
10:54
#258. 200 patients; will be interesting all the same (as an observer).
alphorn
15/1/2018
10:48
15th jan Liberum buy tp 1760p

reiterates

philanderer
15/1/2018
10:47
ImmuPharma end their Phase 3 Lupuzor trial this week and the results are expected to beat GSK's Benlysta.
top tips
15/1/2018
09:15
See your forecast of 1425p this week is looking good NOT.Put a sock in it.Your like an old women.Keep taking the tablets for your Bi-Polar condition.
garycook
15/1/2018
08:19
Health care sector weak today it seems.
montyhedge
12/1/2018
21:33
Dow on fire tonight, Monday watch GSK take off, bears are short and caught. Good weekend all.
montyhedge
12/1/2018
20:10
Strong performance, especially taking account of forex moves.
alphorn
12/1/2018
16:26
GSK receives FDA approval for expanded indication for Fluarix Quadrivalent (influenza vaccine) for persons 6 months and older.
philanderer
12/1/2018
15:40
Yes 1425p next week, my forecast.
montyhedge
12/1/2018
14:51
Nice little rounded bottom
supermarky
12/1/2018
14:36
Another good announcement.
montyhedge
12/1/2018
13:42
This is the one for me, I go with Motley.
montyhedge
12/1/2018
13:37
That guy's research amounts to the solitary fact that GSK is a pharma. Imbecile.
woodhawk
12/1/2018
13:19
Who is this guy Avinnash Gorakssakar?

"I think this is a stock which does not enjoy much liquidity but considering the fact that the pharma cycle is now slow turning around and hopefully I think the way things should pan out for CY2019 I think GlaxoSmithKline Pharmaceuticals should definitely do reasonably better."

How much liquidity does he want?

ianood
12/1/2018
12:54
Hold GlaxoSmithKline Pharmaceuticals, says Avinnash Gorakssakar

According to Avinnash Gorakssakar, Market Expert, one may hold GlaxoSmithKline Pharmaceuticals

Video

Avinnash Gorakssakar, Market Expert told CNBC-TV18, "One can hold on to GlaxoSmithKline Pharmaceuticals because I would believe that this is one company which definitely could deliver good amount of returns over the next say one to two years. I think this is a stock which does not enjoy much liquidity but considering the fact that the pharma cycle is now slow turning around and hopefully I think the way things should pan out for CY2019 I think GlaxoSmithKline Pharmaceuticals should definitely do reasonably better."

"I think keeping 18-24 month kind of horizon one could definitely expect a decent risk reward. Maybe in the short term the stock may not go anywhere, but longer term definitely good risk reward could be made by the investor," he added.

philanderer
12/1/2018
11:50
Emma knows what she is doing, very impressed with her at Pharma Conference San Francisco last week. But like the Motley Fool says, p.e 12 yield 6%.
The thing is shareprice come down from 1725p to 1350p on CEO mentioning may bid for Pfizer consumer div. She won't pay up if she did bid.

montyhedge
12/1/2018
11:49
Looking better this morning :-)
philanderer
12/1/2018
11:43
That has to be one of the most absurd stories i have seen for some time - GSK to take out VEC. It would have absolutely no value to GSK, as VEC makes its money by tie-ups of technology. It also has the old SKP assets of Flutiform delivery and supply chain revenues plus the links to Pacira in the US and a few other royalty bearing assets. GSK currently makes royalty payments of 9M GBP to VEC p.a. (for the ellipta series delivery tech) and is also in a litigation battle over some other royalty rights that were licensed from the original VEC. At best, this is worth 20M GBP in cost savings p.a. GSK would not be able to leverage the VEC technology to competitors. I do think VEC will be in play but much more likely to a generics company looking to leverage delivery technologies across a wide platform.
polaris
12/1/2018
08:24
Great article. https://www.fool.co.uk/investing/2018/01/06/why-glaxosmithkline-plc-shares-could-be-the-buy-of-the-decade/
montyhedge
11/1/2018
23:53
Market report: Takeover chatter swirls around inhaler maker Vectura

The City rumour mill moved back into full swing today following the Christmas lull, speculating that asthma inhaler maker Vectura could be in the crosshairs of pharma giant GlaxoSmithKline, looking to capitalise on its recent share price slump.

City chatter mooted that GSK is preparing to deliver a knockout bid in excess of 175p per share, which would value the company at close to £1.2bn.

Vectura has become vulnerable to a swoop after its share price tumbled 14pc last year and traders have speculated that GSK could be the first to launch an opportunistic bid.

One analyst noted that Vectura’s smart inhaler technology could prove alluring for GSK but added that a move would be a step change as new boss Emma Walmsley attempts to put her stamp on the company.

Vectura’s strategy shift towards partnerships elicited a tepid response from shareholders last week and the company was highlighted by City analysts as one of a handful of mid-cap pharma stocks that are sitting ducks for takeover action. Its shares have been put under pressure by its dispute with US regulators over receiving approval to launch a generic copy of GSK’s Advair drug, as generic drugs snap up more market share.

A final decision is expected from the US Food and Drug Administration during the first quarter of this year. Vectura’s shares were still under the cosh from the looming verdict on Thursday, finishing up 0.5p at 113.9p.

philanderer
11/1/2018
22:49
GSK good rise in US tonight, take off tomorrow.
montyhedge
Chat Pages: Latest  663  662  661  660  659  658  657  656  655  654  653  652  Older

Your Recent History

Delayed Upgrade Clock